Emerging molecular-targeted therapies—the challenging case of endometrial cancer

Ines Vasconcelos

Abstract


Endometrial cancer newly affects an estimated 54,870 women in the United States, being responsible for an estimated 10,170 deaths in 2015. It has demonstrated to harbor a complex carcinogenesis process, with limited treatment options for advanced or persistent disease. Identification and targeting of genetic alterations that lead to progressive disease and therapy resistance is not only challenging, but also often does not correlate with a clinical benefit. Targeted maintenance therapies in endometrial cancer have been largely disappointing. Nonetheless, targeted personalized treatment should be the main goal of treatment of advanced disease in the future. Due to the high variety of drugs being tested in early clinical trials, it is hard to keep pace with the latest developments and ongoing trials. This review aims to summarize the latest published and ongoing trials on targeted therapies in endometrial cancer.

Keywords


Endometrial cancer; targeted-therapy; PIK3/AKT/mTOR; ErbB; VEFG

Full Text:

PDF

References


National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2012 [document on the Internet]. Bethesda:NIH; 2015 [cited date]. Available from: http://seer.cancer.gov/csr/1975_2012/.

Growdon WB, Roussel BN, Scialabba VL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011; 121(1):212-217. doi: 10.1016/j.ygyno.2010.11.039.

Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011; 8(5):261-271. doi: 10.1038/nrclinonc.2010.216.

Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67-73. doi: 10.1038/nature12113.

Peiro G, Peiro FM, Ortiz-Martinez F, et al. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol 2013; 44(2):218-225. doi: 10.1016/j.humpath.2012.05.008.

Bradford LS, Rauh-Hain A, Clark RM, et al. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol 2014; 133(2):346-352. doi: 10.1016/j.ygyno.2014.02.022.

Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 2015; 136(2):246-253. doi: 10.1016/j.ygyno.2014.12.019.

Coleman RL, Sill MW, Thaker PH, et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 138(1):30-35. doi: 10.1016/j.ygyno.2015.04.005.

English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 2013; 209(5):465.e1-465.e9. doi: 10.1016/j.ajog.2013.07.020.

Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015; 33(8):930-936. doi: 10.1200/JCO.2014.58.3401.

Meyer LA, Slomovitz BM, Djordjevic B, et al. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 2014; 24(4):713-717. doi: 10.1097/IGC.0000000000000118.

Kwok B , Rawson R , Alsabeh R et al. Lung adenocarcinoma with contiguous in-situ follicular lymphoma involving <5% of the total lymphoid cells (Abstract LW38.1). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.

Owens SR, Hartman DJ. In situ Follicular lymphoma (Abstract LW25). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.

Alsabeh R, Abdelhalim F, Kwok B, et al. In-situ follicular lymphoma involving about 2% of the total lymphoid cells (Abstract LW103). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.

Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012; 70(1):95-102. doi: 10.1007/s00280-012-1889-8.

Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2014;132(3):585-592. doi: 10.1016/j.ygyno.2014.01.015.

Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):22-27. doi: 10.1016/j.ygyno.2012.12.022.

Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29(24):3278-3285. doi: 10.1200/JCO.2010.34.1578.

Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117(3):473-476. doi: 10.1016/j.ygyno.2010.02.022.

Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 2012;23(1):238-244. doi: 10.1093/annonc/mdr063.

Oza AM, Pignata S, Poveda A, et al. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. J Clin Oncol 2015; published online on June 15. doi: 10.1200/JCO.2014.58.8871.

Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2014;135(2):184-189. doi: 10.1016/j.ygyno.2014.06.033.

Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013;108(5):1021-1026. doi: 10.1038/bjc.2013.59.

Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(3):486-494. doi: 10.1016/j.ygyno.2013.02.019.

Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109(7):1323-1330. doi: 10.1002/cncr.22545.

Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26(26):4319-4325. doi: 10.1200/JCO.2007.15.8808.

Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127(2):345-350. doi: 10.1016/j.ygyno.2012.07.127.

Zhang X, Kyo S, Nakamura M, et al. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells. Cancer Lett 2014;345(1):106-114. doi: 10.1016/j.canlet.2013.11.020.

Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025.

Konecny GE, Finkler N, Garcia AA, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 2015;16(6):686-694. doi: 10.1016/S1470-2045(15)70159-2.

Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127(3):538-543. doi: 10.1016/j.ygyno.2012.08.020.

Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 2012;125(1):136-140. doi: 10.1016/j.ygyno.2011.11.042.

Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259-2265. doi: 10.1200/JCO.2010.32.6397.

McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105(2):508-516. doi: 10.1016/j.ygyno.2007.01.019.

Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(3):441-445. doi: 10.1016/j.ygyno.2014.10.001.

Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134(2):274-280. doi: 10.1016/j.ygyno.2014.05.016.




DOI: http://dx.doi.org/10.30564/amor.v1i1.4

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Ines Vasconcelos

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.